CoChat
Sign Up
Cited by 30Thyroid Disorders and TreatmentsThyroid and Parathyroid SurgeryThyroid Cancer Diagnosis and Treatment

Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis

Laurent, Irakoze, Tang, Siying, Astère, Manirakiza, Wang, Kan Ran, Deng, Shuhua, Xiao, Ling, Li, Qi Fu·2018·Endocrine
DOI 10.1007/s12020-018-1574-8
Open this paper in CoChat — free account

Abstract

Purpose To compare the effectiveness of liquid L-T4 (L-thyroxine) and tablet L-T4 in patients on L-T4 replacement or suppressive therapy.Methods The Cochrane Library, PubMed, Embase, and Web of Science databases were searched to identify relevant articles. All prospective or randomized controlled studies (RCTs) comparing liquid L-T4 and tablet L-T4 in patients on L-T4 replacement or suppressive therapy were included in the analysis.Results Overall, the initial search of the four databases identified 1278 published studies; of these, eight studies were ultimately included in the meta-analysis. TSH (thyroid stimulating hormone) levels were significantly suppressed in patients on liquid L-T4 compared with those on tablet L-T4, in patients on L-T4 suppressive therapy with L-T4 malabsorption (Mean Difference (MD) = -2.26, 95% Confidence Interval (CI): -3.59, -0.93; P = 0.0009)). However, liquid L-T4 and tablet L-T4 did not show a statistically significant difference in patients on L-T4 suppressive therapy without malabsorption (MD = 0.08, 95% CI: -0.31, 0.47; P = 0.69). TSH levels were significantly normalized in patients on liquid L-T4 compared with those on tablet L-T4, in Patients on L-T4 replacement therapy with L-T4 malabsorption (MD = -3.20, 95% CI: -5.08, -1.32; P = 0.0009). However, liquid L-T4 and tablet L-T4 did not show a statistically significant difference in patients on L-T4 replacement therapy without malabsorption (MD = 0.91, 95% CI: -0.03, 1.86; P = 0.06).Conclusion Liquid L-T4 is more efficient than tablet L-T4 in patients on L-T4 replacement or suppressive therapy with malabsorption. No significant differences were observed in patients without malabsorption. Further studies should be conducted to verify these findings.

Integrity signals

Registry

Crossref · 10.1007/s12020-018-1574-8

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A meta-analysis by Laurent et al based on 8 prospective or randomized controlled studies found reduced TSH levels in patients with malabsorption who were taking liquid formulations, but TSH levels did not differ significantly between tablets and liquid preparations in the nonmalabsorption group.

    “As revealed by a meta-analysis by Laurent et al (219) based on 8 prospective or randomized controlled studies, reduced TSH levels were observed in patients with malabsorption who were taking liquid formulations. However, TSH levels did not differ significantly between tablets and liquid preparations in the nonmalabsorption group.”

    From Levothyroxine: conventional and novel drug delivery formulations. (2023) · cites this paper as [219]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Laurent, I., Tang, S., Astère, M., Wang, K. R., Deng, S., Xiao, L., & Li, Q. F.
Affiliations
  • Ministère de la Santé Publique (BI)
  • The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
Corresponding author
Li, Qi Fu
ORCID
Venue
Endocrine
Publisher
Springer Science and Business Media LLC
Published
2018-03-23
Volume
61
Issue
1
Pages
28-35
ISSN
  • 0969-711X (ISSN-L)
  • 1355-008X
  • 1559-0100
DOI
10.1007/s12020-018-1574-8
OpenAlex
W2792790125
Cited by
30
References
49
Citations by year
2026: 2 · 2025: 4 · 2023: 1 · 2022: 7 · 2021: 8 · 2020: 6 · 2019: 2
FWCI
0.62
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Endocrine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China Grants (81370954, 81670785)
  • Fundamental Science and Advanced Technology Research of Chongqing Major Project (cstc2015jcyjBX0096)
  • Chongqing Science and Technology Committee Innovation Project, Technology Development and Application of Precision Medicine (cstc2016shms-ztzx1003)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
levothyroxine, liquid formulation, tablet formulation, thyroid hormone replacement, thyroid-stimulating hormone, TSH suppression, malabsorption, hyperthyroidism
MeSH terms
Humans, Malabsorption Syndromes, Tablets, Thyroxine, Pharmaceutical Solutions, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review